Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

• Published in: Journal of clinical oncology Vol. 36; no. 20; pp. 2017 - 2023
• Main Authors: Young, Annie M, Marshall, Andrea, Thirlwall, Jenny, Chapman, Oliver, Lokare, Anand, Hill, Catherine, Hale, Danielle, Dunn, Janet A, Lyman, Gary H, Hutchinson, Charles, MacCallum, Peter, Kakkar, Ajay, Hobbs, F D Richard, Petrou, Stavros, Dale, Jeremy, Poole, Christopher J, Maraveyas, Anthony, Levine, Mark
• Format: Journal Article
• Language: English
• Published: United States 10.07.2018
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin - therapeutic use; Factor Xa Inhibitors - therapeutic use; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Male; Middle Aged; Neoplasms - blood; Neoplasms - pathology; Pilot Projects; Rivaroxaban - therapeutic use; Survival Rate; Treatment Outcome; Venous Thromboembolism - drug therapy
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2018.78.8034

Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ± 4.5%, assuming a VTE recurrence rate at 6 months of 10%. Results A total of 203 patients were randomly assigned to each group, 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (dalteparin, n = 18; rivaroxaban, n = 8). The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99). The 6-month cumulative rate of major bleeding was 4% (95% CI, 2% to 8%) for dalteparin and 6% (95% CI, 3% to 11%) for rivaroxaban (HR, 1.83; 95% CI, 0.68 to 4.96). Corresponding rates of CRNMB were 4% (95% CI, 2% to 9%) and 13% (95% CI, 9% to 19%), respectively (HR, 3.76; 95% CI, 1.63 to 8.69). Conclusion Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin.